Figure 5. c-Met-specific shRNA-expressing Ad effectively inhibits tumor growth in vivo.

(A) Potent antitumor efficacy of c-Met-specific shRNA-expressing Ad. When U343 human glioma xenograft tumor size reached an average size of 70–100 mm³, tumors were injected with PBS (◊), dl/LacZ (•), or dl/shMet4+5 (○). Tumor growth was monitored and recorded every other day until the end of the study. The arrow represents Ad inoculation. Values represent the means ± SE (7 animals per group). **P < 0.01 compared with PBS- or dl/LacZ-treated groups. (B) Overall survival curve. The percentage of surviving mice was determined by monitoring tumor growth-related events over a period of 55 days. Tumor size over 1500 mm³ was regarded as death. **P < 0.01 compared with PBS- or dl/LacZ-treated groups.